FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer

Season 5 Episode 26  ·  Jul 22, 2021, 09:34 PM
Headliner
Share
Subscribe

Dr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, and expectations for the confirmatory TROPiCS-04 trial.

Share
Subscribe
Next
Analyzing the Advancing Applications for Next-Generation Sequencing in Lung Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air